Latest News About - Immunoglobulin

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Friday, April 23, 2021

5:13:00 AM CEST

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ab
ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
gl
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
my
ne
nl
no
os
pap
pl
ps
pt
ro
ru
se
si
sk
sl
so
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Most reported countries (24h)

Theme countries

AlertLevel (24h)

Alert level graph

 Previous 14 days average

Alert level:
 high   medium   low

Quotes... Extracted quotes

Steven DeSanctis wrote: "We are seeing interest in the size segment and hearing that institutional investors are really interested in adding assets to the size segment. This makes sense to us, as small caps as a percentage of total US equity market exposure is still running well below its 90- year history as investors clamored for large caps, large growth, and the FAANG names. We estimate over $38B has come into small caps over the last five months, the largest inflow since we started tracking the data back to 2006, representing 4.6% of total assets, close to an all-time high. We also estimate about 45% of all flows go towards passive investing, and this drives the performance," External link

en-finance-yahoo Friday, April 23, 2021 4:22:00 AM CEST

Tyler Van Buren wrote: "In our view, the catalytic power of the company's protease platform continues to be underappreciated due to lack of familiarity. First up in 2021, we look forward to data from the MarzAA Phase III trial, which could support a 2023 approval. The Phase I/II trial in Glanzmann thrombasthenia (1,600+ patients) and other indications will also get underway. For Catalyst's complement-targeting proteases, we expect an observational trial to begin shortly in CFI deficiency, which should provide a bolus of patients to enroll in a Phase I for CB 4332 next year. There is also significant upside potential from expansion of CB 4332 into other indications, and from the rest of the complement franchise which includes CB2782-PEG, a novel anti-C3 protease for dry AMD, and other C4b degraders," External link

en-finance-yahoo Friday, April 23, 2021 4:22:00 AM CEST

Shuichi Ishibashi said: “The new and used car markets in the U.S. are doing very well,” External link

en-finance-yahoo Friday, April 23, 2021 4:22:00 AM CEST

Sergey Chemezov said: "We are glad to present the world's first ever registered medication based on a COVID-specific immunoglobulin. I need to point out that this medication is specifically intended for COVID treatment rather than prevention. This new solution will greatly expand the doctors' toolkit to treat COVID-19. In fact, Russia is among the first countries to apply both types of anti-coronavirus immunisation passive (immunoglobulin) and active (vaccine)," External link

labmate-online Friday, April 23, 2021 12:46:00 AM CEST

Михаил Мурашко commented: “We continue to make a portfolio of domestic medication for the prevention and treatment of COVID-19. Following the world's first Sputnik V vaccine, a number of antiviral agents, medication based on monoclonal antibodies that stop the cytokine storm, we were the first to register an immunoglobulin-based medication that will help critically ill patients in a hospital. The new medication will become an additional tool to protect the health of our citizens during the coronavirus pandemic,” External link

labmate-online Friday, April 23, 2021 12:46:00 AM CEST

Patrick Schmidt said: "We are extremely excited to partner with CND Life Sciences on this important initiative to help diagnose those living with synucleinopathies," External link

benzinga Thursday, April 22, 2021 3:55:00 PM CEST

Patrick Schmidt said: "We are extremely excited to partner with CND Life Sciences on this important initiative to help diagnose those living with synucleinopathies," External link

streetinsider Thursday, April 22, 2021 3:36:00 PM CEST

Sergey Chemezov said: "We are glad to present the world's first ever registered medication based on a COVID-specific immunoglobulin. I need to point out that this medication is specifically intended for COVID treatment rather than prevention. This new solution will greatly expand the doctors' toolkit to treat COVID-19. In fact, Russia is among the first countries to apply both types of anti-coronavirus immunization passive (immunoglobulin) and active (vaccine)," External link

labmate-online Thursday, April 22, 2021 12:47:00 PM CEST

Михаил Мурашко commented: “We continue to make a portfolio of domestic medication for the prevention and treatment of COVID-19. Following the world's first Sputnik V vaccine, a number of antiviral agents, medication based on monoclonal antibodies that stop the cytokine storm, we were the first to register an immunoglobulin-based medication that will help critically ill patients in a hospital. The new medication will become an additional tool to protect the health of our citizens during the coronavirus pandemic,” External link

labmate-online Thursday, April 22, 2021 12:47:00 PM CEST

Steven DeSanctis wrote: “We are seeing interest in the size segment and hearing that institutional investors are really interested in adding assets to the size segment. This makes sense to us, as small caps as a percentage of total US equity market exposure is still running well below its 90- year history as investors clamored for large caps, large growth, and the FAANG names. We estimate over $38B has come into small caps over the last five months, the largest inflow since we started tracking the data back to 2006, representing 4.6% of total assets, close to an all-time high. We also estimate about 45% of all flows go towards passive investing, and this drives the performance,” External link

dailymaverick Thursday, April 22, 2021 3:31:00 AM CEST

Tyler Van Buren wrote: “In our view, the catalytic power of the company’s protease platform continues to be underappreciated due to lack of familiarity. First up in 2021, we look forward to data from the MarzAA Phase III trial, which could support a 2023 approval. The Phase I/II trial in Glanzmann thrombasthenia (1,600+ patients) and other indications will also get underway. For Catalyst’s complement-targeting proteases, we expect an observational trial to begin shortly in CFI deficiency, which should provide a bolus of patients to enroll in a Phase I for CB 4332 next year. There is also significant upside potential from expansion of CB 4332 into other indications, and from the rest of the complement franchise which includes CB2782-PEG, a novel anti-C3 protease for dry AMD, and other C4b degraders,” External link

dailymaverick Thursday, April 22, 2021 3:31:00 AM CEST

Eddie J Sullivan said: “As the COVID-19 pandemic continues to have an impact globally, we are committed to working collaboratively with our government to overcome this health crisis. Our team is excited to be advancing SAB-185, a potent fully-human polyclonal antibody therapeutic, that offers a highly-differentiated potential treatment for patients,” External link

4-traders Wednesday, April 21, 2021 10:05:00 PM CEST

Eddie J Sullivan added: “This is a critical time in the fight against COVID-19, particularly as the virus continues to mutate. SAB-185, developed from our proprietary DiversitAb platform, harnesses the native human immune response and allows us to target a polyclonal response, driving high levels of potency not seen before and providing a match against future SARS-CoV-2 mutants. We look forward to continuing to advance both our COVID-19 program and our novel platform to develop potent targeted therapies that address the emergence, mutation, and diversity of today’s diseases,” External link

4-traders Wednesday, April 21, 2021 10:05:00 PM CEST

Steven DeSanctis wrote: "We are seeing interest in the size segment and hearing that institutional investors are really interested in adding assets to the size segment. This makes sense to us, as small caps as a percentage of total US equity market exposure is still running well below its 90- year history as investors clamored for large caps, large growth, and the FAANG names. We estimate over $38B has come into small caps over the last five months, the largest inflow since we started tracking the data back to 2006, representing 4.6% of total assets, close to an all-time high. We also estimate about 45% of all flows go towards passive investing, and this drives the performance," External link

news-yahoo Wednesday, April 21, 2021 9:17:00 PM CEST

Tyler Van Buren wrote: "In our view, the catalytic power of the company's protease platform continues to be underappreciated due to lack of familiarity. First up in 2021, we look forward to data from the MarzAA Phase III trial, which could support a 2023 approval. The Phase I/II trial in Glanzmann thrombasthenia (1,600+ patients) and other indications will also get underway. For Catalyst's complement-targeting proteases, we expect an observational trial to begin shortly in CFI deficiency, which should provide a bolus of patients to enroll in a Phase I for CB 4332 next year. There is also significant upside potential from expansion of CB 4332 into other indications, and from the rest of the complement franchise which includes CB2782-PEG, a novel anti-C3 protease for dry AMD, and other C4b degraders," External link

news-yahoo Wednesday, April 21, 2021 9:17:00 PM CEST

Steven DeSanctis wrote: "We are seeing interest in the size segment and hearing that institutional investors are really interested in adding assets to the size segment. This makes sense to us, as small caps as a percentage of total US equity market exposure is still running well below its 90- year history as investors clamored for large caps, large growth, and the FAANG names. We estimate over $38B has come into small caps over the last five months, the largest inflow since we started tracking the data back to 2006, representing 4.6% of total assets, close to an all-time high. We also estimate about 45% of all flows go towards passive investing, and this drives the performance," External link

en-finance-yahoo Wednesday, April 21, 2021 8:08:00 PM CEST

Tyler Van Buren wrote: "In our view, the catalytic power of the company's protease platform continues to be underappreciated due to lack of familiarity. First up in 2021, we look forward to data from the MarzAA Phase III trial, which could support a 2023 approval. The Phase I/II trial in Glanzmann thrombasthenia (1,600+ patients) and other indications will also get underway. For Catalyst's complement-targeting proteases, we expect an observational trial to begin shortly in CFI deficiency, which should provide a bolus of patients to enroll in a Phase I for CB 4332 next year. There is also significant upside potential from expansion of CB 4332 into other indications, and from the rest of the complement franchise which includes CB2782-PEG, a novel anti-C3 protease for dry AMD, and other C4b degraders," External link

en-finance-yahoo Wednesday, April 21, 2021 8:08:00 PM CEST

Alex Spyropoulos said: "As a blood clot expert, I can tell you it's the most blood-clotting disease we have ever seen in our lifetimes," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Alex Spyropoulos told: "You have as much risk of getting struck by lightning as you have of getting one of these rare blood clots," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Mark Crowther told: "There are some weak risk factors -- for example, airline travel if you fly from Hawaii to Los Angeles," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Mark Crowther added: "Prolonged car trips are risk factors," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Mark Crowther said: "The vaccine, without question, dramatically reduces the risk of any of the Covid-associated blood clots," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Alex Spyropoulos said: "The chances of getting what we are calling vaccine-induced immune thrombotic thrombocytopenia or VITT is one in a million," "The chances of you being hospitalized with Covid is roughly one in 100 for the adult population. The chances of having a blood clot once you are hospitalized is probably one in five or one in six" External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Mark Crowther agreed: "This complication from the vaccine is excruciatingly rare. Certainly more people are going to be killed by handgun in the United States than by these complications," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Mark Crowther said: "Vaccine hesitancy is a real problem. There is no way an average person can understand the magnitude of the risks," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Mark Crowther said: "The blood thinner that is most likely to be used for many of these patients is exactly the one you would use for standard, run-of-the-mill blood clots," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Mark Crowther said: "Any hospital in the United States would be well positioned to manage these blood clotting complications," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Alex Spyropoulos said: "You see a kind of gunk," External link

wfsb Wednesday, April 21, 2021 5:39:00 PM CEST

Alex Spyropoulos said: “As a blood clot expert, I can tell you it’s the most blood-clotting disease we have ever seen in our lifetimes,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Alex Spyropoulos told: “You have as much risk of getting struck by lightning as you have of getting one of these rare blood clots,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Mark Crowther told: “There are some weak risk factors — for example, airline travel if you fly from Hawaii to Los Angeles,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Mark Crowther added: “Prolonged car trips are risk factors,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Mark Crowther said: “The vaccine, without question, reduces dramatically reduces the risk of any of the Covid-associated blood clots,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Alex Spyropoulos said: “The chances of getting what we are calling vaccine-induced immune thrombotic thrombocytopenia or VITT is one in a million,” “The chances of you being hospitalized with Covid is roughly one in 100 for the adult population. The chances of having a blood clot once you are hospitalized is probably one in five or one in six” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Mark Crowther agreed: “This complication from the vaccine is excruciatingly rare. Certainly more people are going to be killed by handgun in the United States than by these complications,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Mark Crowther said: “Vaccine hesitancy is a real problem. There is no way an average person can understand the magnitude of the risks,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Mark Crowther said: “The blood thinner that is most likely to be used for many of these patients is exactly the one you would use for standard, run-of-the-mill blood clots,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Mark Crowther said: “Any hospital in the United States would be well positioned to manage these blood clotting complications,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Alex Spyropoulos said: “You see a kind of gunk,” External link

eastbaytimes Wednesday, April 21, 2021 12:03:00 AM CEST

Alex Spyropoulos said: “As a blood clot expert, I can tell you it’s the most blood-clotting disease we have ever seen in our lifetimes,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Alex Spyropoulos told: “You have as much risk of getting struck by lightning as you have of getting one of these rare blood clots,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Mark Crowther told: “There are some weak risk factors — for example, airline travel if you fly from Hawaii to Los Angeles,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Mark Crowther added: “Prolonged car trips are risk factors,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Mark Crowther said: “The vaccine, without question, reduces dramatically reduces the risk of any of the Covid-associated blood clots,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Alex Spyropoulos said: “The chances of getting what we are calling vaccine-induced immune thrombotic thrombocytopenia or VITT is one in a million,” “The chances of you being hospitalized with Covid is roughly one in 100 for the adult population. The chances of having a blood clot once you are hospitalized is probably one in five or one in six” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Mark Crowther agreed: “This complication from the vaccine is excruciatingly rare. Certainly more people are going to be killed by handgun in the United States than by these complications,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Mark Crowther said: “Vaccine hesitancy is a real problem. There is no way an average person can understand the magnitude of the risks,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Mark Crowther said: “The blood thinner that is most likely to be used for many of these patients is exactly the one you would use for standard, run-of-the-mill blood clots,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Mark Crowther said: “Any hospital in the United States would be well positioned to manage these blood clotting complications,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Alex Spyropoulos said: “You see a kind of gunk,” External link

mercurynews Tuesday, April 20, 2021 11:20:00 PM CEST

Paul Beck disse: “A proteção contra o colostro é um evento crítico, então os produtores devem garantir que os bezerros se levantem e suguem. É fácil perder bezerros recém-nascidos em áreas remotas de pastagens. Isso é particularmente provável de acontecer se a vaca permanecer deitada. ” External link

beefpoint Monday, April 19, 2021 5:57:00 PM CEST

Jessika Ricarte diz: “O médico colocou um oxímetro nele. Os níveis de oxigenação de Lucas estavam em 86%. Agora sei que isso não é normal” External link

odocumento Saturday, April 17, 2021 12:32:00 AM CEST

Jessika Ricarte diz: “Um bebê não diz o que está sentindo, então dependemos de testes” External link

odocumento Saturday, April 17, 2021 12:32:00 AM CEST

Jessika Ricarte conta: “Na época, o hospital não tinha nem ressuscitador” External link

odocumento Saturday, April 17, 2021 12:32:00 AM CEST

Jessika Ricarte diz: “Quando ele ouviu nossas vozes, começou a chorar” External link

odocumento Saturday, April 17, 2021 12:32:00 AM CEST

Elizabeth Phillips fordert: „Wir müssen geimpft werden, wir müssen es erproben, um die Pandemie zurückzudrängen“ External link

focus Monday, December 28, 2020 11:33:00 AM CET

Most associated names

Daily number of articles in this category

Trend data not available for this selection.